139.09
+0.565(+0.41%)
Currency In USD
| Previous Close | 138.52 |
| Open | 138.46 |
| Day High | 140.2 |
| Day Low | 136.96 |
| 52-Week High | 195 |
| 52-Week Low | 110.04 |
| Volume | 531,214 |
| Average Volume | 1.49M |
| Market Cap | 20.39B |
| PE | 13.2 |
| EPS | 10.54 |
| Moving Average 50 Days | 136.1 |
| Moving Average 200 Days | 135.39 |
| Change | 0.56 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $476.63 as of September 30, 2025 at a share price of $139.085. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $490.29 as of September 30, 2025 at a share price of $139.085.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
GlobeNewswire Inc.
Sep 28, 2025 11:30 PM GMT
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
GlobeNewswire Inc.
Sep 24, 2025 11:30 AM GMT
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
GlobeNewswire Inc.
Sep 23, 2025 8:30 PM GMT
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for